Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC497348 | PMC |
| http://dx.doi.org/10.1136/jnnp.22.1.50 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case series: Three cases of Morvan's syndrome as a rare autoimmune disorder with anti-Caspr2 antibody.
Medicine (Baltimore)
October 2024
Clinical Department of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.
Article Synopsis
- Morvan syndrome is a rare autoimmune disorder primarily affecting males, characterized by symptoms like muscle twitching, autonomic disturbances, and severe sleep issues, often linked to specific autoantibodies.
- Current treatments include various immunotherapies, but no long-term cure exists, prompting interest in alternative therapies like traditional Chinese medicine.
- Three patients with serum Caspr2-positive Morvan syndrome showed some relief from traditional treatments but experienced disease recurrence, indicating the complexity and unpredictability of the condition.
Autosomal Recessive Myotonia Congenita in an Adolescent Boy With Novel Mutation: A Case Report With Discussion on Management.
Cureus
February 2024
Pediatric Neurology, Jagannath Hospital, Bhubaneshwar, IND.
Congenital myotonia represents a rare group of genetically inherited conditions. It can be either autosomal dominant (Thomsen) or autosomal recessive (Becker). It is characterized by muscular hypertrophy, proximal weakness, and myotonia, or impaired relaxation after contraction.
View Article and Find Full Text PDFCharacterization of cannabis use by patients with myotonic dystrophy type 1: A pilot study.
Neuromuscul Disord
March 2021
Pharmacology-physiology Department, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean (Chicoutimi University Hospital), Saguenay, QC, Canada; Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-St-Jean sur les innovations en santé, Sherbrooke University, Longueuil/Saguenay, QC, Canada. Electronic address:
The treatment of myotonic dystrophy type 1 (DM1) focuses on reducing symptom burden. However, since medication often fails to produce satisfying symptom relief, some patients seek alternatives, such as cannabis, to help reduce some of these symptoms. The aim of this study was to provide an accurate profile of cannabis use among DM1 patients.
View Article and Find Full Text PDFRationale: Myotonic dystrophy type 1 (DM1) is an autosomal-dominant disorder associated with a short life expectancy and various symptoms, including grip myotonia. Even though grip myotonia decreases quality of life, activities of daily living (ADLs), and work performance, very few interventions provide symptomatic relief.
Patient Concerns: In this case report, we present a patient with DM1 and gradually worsening grip myotonia.
A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients.
J Neurol
February 2020
Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University Munich, Ziemssenstr. 1, 80336, Munich, Germany.
Background: The symptomatic treatment of myotonia and myalgia in patients with dystrophic and non-dystrophic myotonias is often not satisfactory. Some patients anecdotally report symptoms' relief through consumption of cannabis.
Methods: A combination of cannabidiol and tetrahydrocannabinol (CBD/THC) was prescribed as compassionate use to six patients (four patients with myotonic dystrophy types 1 and 2, and 2 patients with CLCN1-myotonia) with therapy-resistant myotonia and myalgia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!